Effects of Trastuzumab Combined with Neoadjuvant Chemotherapy on Clinical Efficacy and Related Index-es of Breast Cancer Patients after Surgery / 中国药房

ABSTRACT

OBJECTIVE:To investigate the effects of trastuzumab combined with neoadjuvant chemotherapy on clinical effica-cy of breast cancer patients,serum angiogenic factors and apoptosis factors of breast tissue. METHODS:A total of 116 breast can-cer in patients were selected from our hospital during Jan. 2012-Dec. 2014 as research object,and then divided into control group and observation group according to random number table,with 58 cases in each group. Control group was given Carboplatin for in-jection 100 mg(added into 500 mL 5% Glucose injection after diluted into 10 mg/mL),ivgtt,200-400 mg/m2 on the first day of each chemotherapy cycle;Docetaxel injection ivgtt,75 mg/m2 on the first day of each chemotherapy cycle. On the basis of control group,observation group was additionally given Trastuzumab for injection,4 mg/kg in the first week,2 mg/kg in the 2nd-8th week,once a week,ivgtt. A treatment course lasted for 3 weeks,and both groups received 6 courses of treatment. Both groups re-ceived modified radical mastectomy 2 weeks after treatment. The levels of serum angiogenic factors and apoptosis factors of breast tissue were observed in 2 groups before and after treatment. Clinical efficacies and the occurrence of ADR were compared between 2 groups 1 year after treatment. RESULTS:Before treatment,there was no statistical significance in the levels of serum angiogenic factors and apoptosis factors of breast tissue between 2 groups (P>0.05). After treatment,the levels of serum angiogenic factors and apoptosis factors of breast tissue were decreased significantly in 2 groups,and the observation group was significantly lower than the control group,with statistical significance(P0.05). CONCLUSIONS:Trastuzumab combined with neoadjuvant chemotherapy is helpful to improve the therapeutic effect with breast cancer, prevent recnrence,and reduce the expression of serum angiogenic fac-tors and apoptosis factors of breast tissue with good safety.